DAWEI(SZ:002213) Zheng Quan Zhi Xing·2025-08-29 17:15Core Viewpoint - The announcement confirms that the conditions for the second exercise period of the stock option plan have been met, allowing eligible participants to exercise their options [1][20][25]. Summary by Sections Stock Option Plan Overview - The stock option plan involves the issuance of 151,530 stock options at an exercise price of 12.409 CNY per share [1][22]. - The eligible participants include 11 individuals, primarily middle management and core technical/business personnel [22][24]. Exercise Conditions - The second exercise period is defined as the period from 24 months after the initial grant date until 36 months after, with a 30% exercise ratio [17][23]. - The performance targets for the exercise periods are based on revenue growth rates, with specific targets set for 2023, 2024, and 2025 [5][19]. Performance Assessment - The performance assessment will be conducted annually, with specific revenue growth targets set at 20% for 2023, 30% for 2024, and 60% for 2025, based on the 2022 revenue of 560.3494 million CNY [5][19]. - The company will evaluate individual performance based on a set of criteria, determining the actual number of options that can be exercised [6][19]. Approval Process - The plan has undergone various approvals, including board meetings and shareholder meetings, ensuring compliance with legal and regulatory requirements [8][9][10]. - The company has received independent opinions from financial advisors and legal counsel confirming the validity of the exercise conditions [26][27]. Financial Impact - The exercise of options will increase the total share capital by 151,530 shares, with minimal impact on earnings per share and overall financial results [24][25]. - The funds raised from the exercise will be used to supplement the company's working capital [24]. Conclusion - The company confirms that all conditions for the second exercise period have been met, and the eligible participants can proceed with exercising their options [20][25].